Could a diabetes drug help kidney patients lose weight?
NCT ID NCT07176663
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests the safety and effectiveness of tirzepatide (Spartina) for weight loss in 15 adults with chronic kidney failure who also have diabetes or obesity. Participants receive weekly injections for three months. The goal is to see if this drug can help manage weight and blood sugar without the risks of other treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Tirzepatide (Spartina)
- What this could lead to
- If it works, this could point toward a way to help people with kidney failure lose weight and manage diabetes without the side effects of other drugs.
- What could go wrong
- This is a very small, early study with only 15 people, so results may not apply to everyone. The drug may not work as hoped or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nooshin Dalili
Tehran, 1666663421, Iran
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can a Two-Drug combo tip the scales against obesity?
- Can Weight-Loss surgery change how medications work?
- Coffee grounds probiotic could reshape gut health and fight inflammation
- Can shedding pounds reboot the Heart's exercise engine?
- Can stomach surgery alter how painkillers work?